Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...

When Opill became available a year ago, public health experts anticipated it would benefit women without health insurance and those residing in rural areas. The goal was to boost access to ...

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach ...

This episode of Pharma Pulse covers Novo Nordisk’s FDA win for Wegovy in MASH-related liver fibrosis, new research on a ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

Novo Nordisk stock rallies as the Danish pharma giant makes two big announcements. TD Cowen analysts recommend buying NVO ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Investors eyed risks around a high-stakes US-Ukraine meeting, kicking off a week dominated by a Federal Reserve speech that ...

Live Updates Live Coverage Has Ended Monday Wrap-up 4:11 pm The Vanguard S&P 500 ETF closed at 591.36 Monday, down 0.04%.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.